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CORRESPONDENCE
Should third-generation cephalosporins be
avoided against AmpC-inducible
Enterobacteriaceae?
We have previously argued that clinicians should
avoid third-generation cephalosporins against
infections caused by Enterobacteriaceae with
inducible AmpC b-lactamases (Enterobacter, Cit-
robacter freundii, Serratia and Morganella), because
of the likelihood of selecting derepressed mutants
[1]. This view developed from many case reports
published during the 1980s [2], culminating in a
multicentre analysis of Enterobacter bacteraemia
by Chow et al. [3], who observed the selection of
derepressed mutants in 19% of cephalosporin-
treated patients. In a recent letter in CMI, Gold-
stein [4] suggests that we over-estimate the
selection risk and proposes that third-generation
cephalosporins can safely be used for most
infections caused by AmpC-inducible Enterobac-
teriaceae. While we agree that there is confusion
in this area and that some of the evidence is
conflicting, we do not agree with his conclusions.
His view is based on three contentions: (i) that
Chow et al. [3] reviewed few patients and that
others have found less-frequent selection of
resistance; (ii) that we do not advocate avoidance
of all drugs that select resistance; and (iii) that
other treatment options against AmpC-inducible
Enterobacteriaceae carry significant (if different)
risks.
It is true that Chow et al. [3] described selection
of derepressed mutants in only six (19%) of 31
patients receiving cephalosporins (among 129
Enterobacter bacteraemias), whereas a general
review on emerging resistance [4] found selection
by cephalosporins in 6.1% of patients with
AmpC-inducible pathogens (10.1% for Enterob-
acter), with no selection in bacteraemia. However,
it is misleading to dismiss the study by Kaye et al.
[6], who showed a higher failure rate than Fish
et al. [5], on the grounds that MICs were not
reported. Kaye et al. [6] emphasised that their
estimate of the overall selection risk for cepha-
losporin resistance in Enterobacter (19%) agreed
with that of Chow et al. [3], whilst they found a
higher selection rate (29%) in bacteraemia. The
work of Jacobson et al. [7] is also relevant. These
authors analysed data from patients’ charts in a
large case-controlled study, and found a close sta-
tistical association between cephalosporin therapy
and the isolation of AmpC-derepressed Entero-
bacter spp.
Turning to the second contention: it is true that
we do not suggest that clinicians should avoid
every antibiotic where there is a risk of selecting
resistance. However, most of the examples cited
in this context by Goldstein [4] concern Pseudo-
monas aeruginosa and Mycobacterium tuberculosis.
P. aeruginosa can develop single-step mutational
resistance to virtually any ‘antipseudomonal’
antibiotic [8], and the selection risk seems greater
with imipenem than with ceftazidime, ciprofloxa-
cin or the aminoglycosides [9] – a very different
scenario to that with Enterobacter. In the case of
M. tuberculosis, the drugs mentioned by Goldstein
(streptomycin, isoniazid, rifamycins and fluoro-
quinolones) are used in triple combination pre-
cisely to militate against selection of resistance.
Last, Goldstein suggests that third-generation
cephalosporins are preferable to fourth-genera-
tion analogues, which he argues may select
broader resistance contingent on impermeability
and efflux, and imipenem, which he describes as
less active, more toxic, harder to administer and
prone to select other resistance in the same
species. We hold no brief for fourth-generation
cephalosporins, but note that the permeability
and efflux mutations that they mostly select
in vitro [10] are infrequent in vivo, perhaps
because they impede nutrition or adhesion. We
dispute the statements regarding imipenem.
Although its MICs for susceptible Enterobacteri-
aceae are slightly higher than those of third-
generation cephalosporins, imipenem is more
rapidly bactericidal, primarily because it binds
to PBP-2 rather than PBP-3 [11]. As regards
adverse events, imipenem is not associated with
a raised seizure risk so long as high doses are
avoided [12], and very rarely selects for resistance
in Enterobacteriaceae (the exceptions being a few
instances of its selecting porin-deficient mutants
of the epidemic TEM-24+ Enterobacter aerogenes
strain that is prevalent in Belgium and France
[13]). Moreover, imipenem is not the sole carb-
apenem, and other analogues may be more
appropriate in some settings; thus meropenem
may have a lesser protoconvulsive effect [14],
whilst ertapenem allows a once-daily regimen.
Based on these arguments, we contend that
the long-standing caution is correct, and that
third-generation cephalosporins should be avoi-
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ded in severe Enterobacter (especially), C. freundii,
Serratia and Morganella infections, especially as
there are good therapeutic alternatives with less
risk. The exception would be urinary tract
infections, where the high cephalosporin concen-
trations can overwhelm even derepressed mu-
tants. Finally, the consequences of selecting
derepressed mutants should be re-emphasised.
Recent work by Cosgrove et al. [15] suggested
that selection of cephalosporin resistance in
Enterobacter spp. during therapy was associated
with a doubling of mortality, a median 9-day
increase in hospital stay, and an attributable
cost ⁄ patient of $29 000.
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Use of inhaled ampicillin–sulbactam
against multiresistant Acinetobacter
baumannii in bronchial secretions of
intensive care unit patients
Acinetobacter baumannii is responsible for a wide
range of nosocomial infections, often associated
with ventilated patients in intensive care units
(ICUs) [1]. In a recent Clinical Microbiology and
Infection review, Levin [2] suggested that ampi-
cillin–sulbactam could be used for the treatment
of acinetobacter infections. Most supporting stud-
ies have used intravenous or oral forms of this
antibiotic combination. Here we report the use of
an aerosolised form of ampicillin–sulbactam for
the treatment of ventilated ICU patients.
Twenty intubated, mechanically ventilated
patients (12 male and eight female; aged
38–70 years) were enrolled in the study. Multi-
resistant A. baumannii, sensitive only to ampicillin–
sulbactam, was isolated from the bronchial
secretions of each patient (107)108 CFU ⁄mL).
Patients were randomly assigned to receive
ampicillin–sulbactam in either combined aeroso-
lised and intravenous form (ten patients) or only
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